Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There is a debate because:
1. There is no scientific angle to attack against.
2. Desperate times calls for desperate measures.
3. I've noticed double standards against Anavex for a while now.
This is wrong for them to do while other BP does the same thing.
Oh my, TAXES now.... Lol, lets go after those 5 gallon water bottles that they refill every week next.
Good to see you still hanging around JBG. Good luck to you with your trades.
Back that up with the data please. Links. This was discussed before as most of his compensation is in the form of stock options at different levels and prices.
I hope to see Missling follow through with his vision. Hate to see some BP schmuck get all the credit for the last few months of work on a-273.
I think its the understanding of the difference between 5% and .05%
5% is .05 of all shares. I believe its what eagle was trying to say.
Whats the chances of having .049 AND having a load of call options to increase their % even more?
I could see the pps increase above their strike just to exercise their calls.
That's what I took it as. Shareholders could exercise their right, right being 1 share of the pre-required day, to purchase a share at a set price the board approved.
Maybe because they want to be sure to get it designed right. If one wants quick trials, I hear NTRP should be ones huckleberry.
This will be one smooth running BP if they are given a chance to mature. Top notch CEO and a board that does what's best in the interest of its shareholders.
Its actually from the latest pr.
I believe that Missling is preparing the company to defend against one though. Maybe there was an offer and he turned it down knowing Anavex is worth a lot more. So as a precaution, this is in play as well as the Shareholder rights plan.
Imagine this scenario:
Biogen tested our drug and found it to work better than their own MS drug. On top of that, Biogen knows that their Alzheimer candidate is inferior to our drug. So why would they license MS, leaving the other cash cow available for someone else?
Then theres Axon and their ceo and hedge fund crooks. They seem to have the resources to launch a take-over knowing how much spent now would return to them later in multiples.
Lakeshore, I believe the date was feb 17
I got mine for Fidelity and Robinhood. Voted already, but will mail in my vote anyway.
Whats the point?
People don't survive Alzheimer's disease. So imagine how much people pass away before even reaching 85 to meet that statistic.
Taken from the same Alzheimer Association is this:
• Every 66 seconds, someone in the United States
develops Alzheimer’s.
• By mid-century, someone in the United States will
develop the disease every 33 seconds.
https://www.alz.org/documents_custom/2016-facts-and-figures.pdf
page #22
A confirmation that we may be on to something with our pipeline.
First, read THIS, which was published 3 days ago:
"Abnormal levels of calcium in the mitochondria, the cell’s powerhouse, may lead to neuronal death in Alzheimer’s disease and dementia, according to researchers at Temple University’s Center for Translational Medicine"
A topic at ADPD, "CALCIUM STORES IN ANIMAL MODELS OF AD" which will be discussed by Weizmann Institute, which is where Dr. Fisher works and where we got A-371 from. HERE
"Extensive research in the past two decades has focused on amyloid plaques in Alzheimer’s disease (AD) patients, suggesting that their removal will stop/slow the disease process. Despite increasing past and present evidence, these studies neglected to address the possible involvement of calcium handling machineries in the initial causes of functional and structural deterioration in neurons, associated with AD"
A-273 also relates to the below pr if one just read the entire pr vs what is quoted below.
Then, in a pr from Anavex just about 3 years ago is this:
"The scientific findings indicate that too much calcium signaling in neurons may be involved in causing Alzheimer’s disease (AD). These calcium alterations can be modulated directly through the inositol triphosphate (IP3) receptor, representing a potential new therapeutic approach to treating AD. The findings indirectly confirm the therapeutic opportunity in Alzheimer’s disease for ANAVEX PLUS, an agonist of the sigma-1 receptor (S1R), because the S1R acts as a calcium signaling modulator via IP3." which can be viewed in its entire pr HERE.
TIC TOC TIC TOC goes the clock
Only a matter of time before we go BOOM
To be fair, I didn't say he wasn't part of the trial anymore. I just saw on his LinkedIn and shared with everyone something I found.
Others take information like that and turns it into "fake news"
Hahaha
Lol the confusion attempt is real. In a couple weeks, we will hear from the horses mouth. In the meantime, I'll tuck away my shares and wait for news vs making it up.
Would Macfarlane leaving Alfred Health have anything to do with the start date of p2/3? According to it, he left in June 2016.
Taken from his linkedin: HERE
Director/Associate Professor, Aged Psychiatry
Company NameCaulfield Hospital (Alfred Health)
Dates Employed2008 – Jun 2016 Employment Duration8 yrs 6 mos
As the longest-serving Director of Aged Psychiatry in this position since the creation of the Department in 1994, I ran a 40-EFT aged psychiatry service in south-east Melbourne, comprising a 15-bed acute inpatient unit, a community case management service and a liaison psychiatry service to some 300 aged care, rehabilitation and acquired brain injury beds.
My time was split between administration, teaching, working as the acute inpatient consultant on the ward, and running a clinical trials/research unit that deals primarily with industry-sponsored trials of potential disease-modifying agents for Alzheimer's disease.
I think I read that each share would have an option to exercise their right to buy a share at a said price.
Think someone could break down all the rights this would give so the common person could understand what the shareholder rights would actually do for us?
Yes, which could be the reason Missling is on the conference tour trying to get the name out.
In this crooked game where BP livelihoods could vanish, anything is possible because we are a threat to them. To think they aren't circling us from above like vultures is foolish. We already survived one playbook thrown at us and here we still stand.
A 1:4 to get on the Nasdaq yes. A 1:32 would look a bit suspicious no?
One could get the idea that Biogen got the results and are impressed with it,but isn't offering enough to make Missling say yes.
I had to read what you wrote and I like the way they twisted your words around. I understand what you meant. Reviewed by peers and peer reviewed is two totally different meanings.
Bryostatin might have peer reviewed articles but their data will be reviewed and ridiculed by peers on how 3 months of an Alzheimer's trial can hold any water.
Nice post,
Yes things could have been a lot worse, but his finance skills shined and didn't allow us to dilute when everyone expected him to.
The worse they can say is " no placebo, everyone knows they taking a drug" what they don't say is they know they taking a drug, and 99% of the time the trial fails.
It's been pretty bearable this last few days, meaning we should be climbing steps again. Hopefully that elusive mountain peak soon.
Its still an OTC. Didn't up list yet.
Blueberry's, if taken for 12 weeks just like how Bryostatin will have been, shows promise that it too can make a meaningful, positive effect against alzheimers. Blueberry juice did better in helping improve memory over the placebo in a blind study. See below for the 3 month data readout.
"This study indicated that wild blueberry juice supplementation for 12 weeks improved memory function in older adults with early memory decline. To our knowledge, this is the first human trial assessing the potential benefit of blueberry supplementation on neurocognitive function in older adults with increased risk for dementia."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850944/
So how would you feel about a trial that would run for ONLY 3 months?
Because you know, there IS this one company that believes 3 months is enough of a p2 to see the results before moving on to a p3.
Looks like you got your publicity question answered today.
These two tweets 15 hours ago puts the urgency into reality
https://twitter.com/bio1x1
#Alzheimer’s disease costs Japan 14.5 trillion yen in direct and indirect costs, and 600-800 billion dollars globally
In 2035, 1/3 of the Japanese population will reach the age of 65. #BIOASIA17
After doing the foolish mistake of investing in APHQF when the $1M pr came out they invested in Tetra, and recommending to a friend to buy GRPOF when it was $.18 I closed my position and opened one here for the long haul. Hope to be a positive contributor here just as I try to be at my other long hold of AVXL.
Well, to be fair I emailed IR and showed them a way their website can be accessed via anything that they uploaded. I showed them how there's was and how it should block all other pages if it wasn't a direct page. Glad they listened and fixed it because one could have monitored that page and viewed it before they made the link public. Come to think of it, it probably was like that back in 2015 when we had the infamous pr and naked shorting right after.
Do I need to provide a screen of my email and their reply for everyone to believe?
Yes, I know of that one also because its the day April options expire.
Bottom line, we need something to advance. Either a p2 to start or p2/3 Alzheimer's.
Im done responding today as I ran out of posts. Have a great one everyone
Exactly. Which is why IMO, they are shooting for a buyout vs going the distance. 3 month trial is a pretty safe point to stop the trial. Limit the risk and move on to p3 fast before p2 shows the ever familiar decline. Wait, the company is RUSHING the trial for the patients.......
With Silverman Chairman of the Board, I highly doubt that.
LOL, this graph and that explanation has been tried before
Iroquois Master Fund is a little scary.Iroquois Master fund is a Cayman Islands exempted limited company.Read This
Joshua Silverman Co-Founder, Managing Partner, and Managing Member, Iroquois Capital Management L.L.C.
Iroquois seems to buy large stakes in companies, then recommend their selection be added to the board, which they then use their new stake to vote for.
Whats the address of Neurotrope? Taken directly from their site.
Corporate Address
Neurotrope BioScience,
205 East 42nd Street, 16th Floor
New York, NY 10017
Phone: (973) 242-0005
Whats the address of Iroquois Capital Management L.L.C.? Thats right here
205 East 42nd Street
16th Floor
New York, NY 10017
United States
So who did Iroquois recommend to have on Neurotrope board?HERE
Also part of the settlement is the resignation of Paul E. Freiman and Jay M. Haft from the company’s board of directors, effective immediately. The board has appointed Joshua Silverman chairman of the board and Kenneth J. Gorelick to the board, also effective immediately.
So we have Iroquois's Joshua Silverman, co-founder of Iroquois capital management llc, receiving the chairman of the board,
and Gorelick not only to the board, but also Chief Medical Director.
I'm starting to see your concern Xena. Chief Medical Director could be nothing more than a puppet for Silverman
Which could be the reason why we see Alzheimers trial only at 3 months.
Dare I argue though that the low n count received something no other Alzheimer patient ever received, IMPROVEMENT and/or STABILIZATION.
uh, no
When Anavex releases their data,IMO, it WILL be positive. The same nay-sayers will say its meaningless because the n is too low. Dare I argue though that the low n count received something no other Alzheimer patient ever received, IMPROVEMENT and/or STABILIZATION.
Yet, here we are arguing about placeholders?
Look at Xena sticky about 6 presentations
Blanchette Rockefeller Neurosciences Institute IS Neurosciences Research Ventures, Inc., at least thats what I get from the SEC filing:
https://www.sec.gov/Archives/edgar/data/1618058/000119312516655870/0001193125-16-655870-index.htm
Except now BRNI is now Cognitive Research Enterprises.
BRNI owns 10M shares pre-rs. They would gain the most, as they are the ones that licensed Bryostatin-1 to Neurotrope. Just thought I'd throw that out there.
They simply removed the abstract link from the schedule:
A03.f. Drug Development, Clinical Trials: Neuroprotective and mitochondrial compounds
The direct link still works, so more than likely they had to remove the old stuff that was on there, and come the day that the company PR the news, the link will then be filled with the newest data.
I like that the Dr. went to Asia for a conference, where 28% of all attendees attend it at that region. Only one higher is the North America one in San Diego, which is 31%.
Then theres adpd in Austria, which 46% of all attendees are from Western Europe. Good exposure for those outside of the U.S. to the company.
I guess it was a bad thing that AF said positive things about NTRP. Good thing there's tutes already holding a significant amount of shares already.